Xeljanz Lawsuit Updates & News (2025)

ConsumerShield

Editor

November 1, 2023 Read in 2 mins

This year, attorneys are also addressing the Xeljanz-blood clot lawsuits for the victims. Due to this reason, victims still have a chance to have the rightful compensation through legal guidance and support. By far, there are no declared court settlements and hearings for the Xeljanz-blood clot lawsuit.

Free Case Review

Preparing Case Review Form. ConsumerShield is transforming the way consumers experience law.

A recent study conducted by Harvard researchers has uncovered a notable link between the use of certain inflammation and autoimmune treatment drugs, such as Xeljanz and Rinvoq, and a heightened risk of developing acne. This study, published in the Journal of the American Medical Association Dermatology, delves into the effects of a class of medications known as Janus Kinase (JAK) inhibitors.
The comprehensive research involved a systematic review and meta-analysis of 25 studies, encompassing over 11,000 participants. It specifically focused on the effects of JAK inhibitors, particularly those targeting JAK1, a combination of JAK1 and JAK2, and tyrosine kinase 2-specific inhibitors, with an emphasis on their potential side effects, including acne.
The findings were significant: patients using JAK inhibitors were found to be four times more likely to develop acne compared to those not on these medications. More precisely, the risk of acne in patients on JAK inhibitors was 3.83 times higher than in those taking a placebo, highlighting a concerning side effect of these commonly used treatments.
In April, scientific findings supported this allegation which included the conference of the British Society for Rheumatology 2023. It established the link between Janus Kinase inhibitors present in Xeljanz that boost the chances of cancer development among the victims.
This includes research in Annals regarding rheumatic diseases, which states that severe cardiovascular fluctuations take place among the victims who are exposed to tofacitinib as compared to tumor necrosis among these patients.
The European Medicines Agency imposed constraints on the prolonged usage of Xlejanz so that people can be in minimal contact with this drug, which can cause cardiac problems and blood clot development among them as well.